{"organizations": [], "uuid": "350c07bd3e76c5e2341670b52feede5bd3c8e1ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530755?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "TauRx Pharmaceuticals completes $135mm financing", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "TauRx Pharmaceuticals completes $135mm financing", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T02:40:00.000+03:00", "replies_count": 0, "uuid": "350c07bd3e76c5e2341670b52feede5bd3c8e1ec"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530755?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "TauRx Pharmaceuticals completes $135mm financing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "TauRx Pharmaceuticals completes $135mm financing Deal Date: Oct-01-2015 / Deal # 201530755 Executive Summary \nIn a late-stage round of tranched financing that initiated in March 2015, TauRx Pharmaceuticals Ltd. (drug candidates and diagnostics for neurodegenerative diseases) raised $135mm from new and existing investors. TauRx will use the money for its Phase III trials of the tau aggregation inhibitor LMTX in mild-to-moderate Alzheimer's disease. The company completed enrollment in September 2014 and studies are currently in progress; top-line results are expected in 2016.", "external_links": [], "published": "2015-10-16T02:40:00.000+03:00", "crawled": "2015-10-16T19:15:07.335+03:00", "highlightTitle": ""}